

# Quantitative Systems Toxicology (QST) Modeling of Drug-Induced Liver Injury and Adaptation

October 28, 2020

Kyunghee Yang

*DILIsym Services*

**S+** A SIMULATIONS PLUS COMPANY

# Session Description and Objectives

## *Description*

- This talk will present how quantitative systems toxicology (QST) modeling can aid in evaluating potential drug-drug interactions (DDIs) at the hepatotoxicity mechanism level and exploring mechanisms underlying adaptation to drug-induced liver injury (DILI)
- A case study will be presented where DILIsym, a QST modeling platform, was employed to assess potential DILI DDIs between metformin and solithromycin

## *Objectives*

- To understand drug-drug interactions (DDIs) at the hepatotoxicity mechanism level that may lead to enhanced drug-induced liver injury (DILI)
- To describe the application of quantitative systems toxicology (QST) modeling in prediction of DILI DDIs
- To describe how QST modeling can be employed to assess mechanisms underlying adaptation to DILI

# Biography and Contact Information

- Scientist for DILIsym Services, Inc. and software developer working on the DILI-sim Initiative modeling team
- Research focuses on the quantitative systems toxicology (QST) modeling of drug-induced liver injury (DILI) regarding interference of bile acid transport, inhibition of mitochondrial function, and induction of oxidative stress by hepatotoxic drugs
- B.S. in pharmacy and M.S. in pharmacokinetics from Seoul National University, South Korea; Ph.D. in Pharmaceutical Sciences from University of North Carolina at Chapel Hill
- Published scientific papers in the areas of drug metabolism and transport, regulation of drug metabolizing enzymes during pregnancy, and QST modeling of DILI
- Email: [kyang@DILIsym.com](mailto:kyang@DILIsym.com)

# Introduction: Drug-Induced Liver Injury (DILI) and Adaptation

## Drug-induced liver injury (DILI)

- One of the primary reasons for termination of drug development programs
- Induced by multiple mechanisms
- Can be enhanced by polypharmacy if co-administered drugs induce toxicity via mechanisms that have overlapping pathways (DILI-DDI)

## Adaptation


- Resolution of DILI despite continued drug dosing
- Commonly observed in clinical trials, but the underlying mechanisms behind this phenomenon remain unclear

## Quantitative systems toxicology (QST) modeling


- Predicts toxicity by integrating drug exposure, mechanisms, and inter-patient variability

**The objective was to predict potential DILI-DDIs of metformin and solithromycin and the impact of mitochondrial biogenesis on DILI using QST modeling**

**Reasons for Termination of Programs due to Safety by Organ System [1]**




## QST Modeling of DILI




# Methods: Quantitative Systems Toxicology (QST) Modeling of DILI-DDI and Adaptation

- DILIsym is a QST software platform that represents drug exposure, liver biochemistry, and multiple mechanisms contributing to DILI and adaptation
  - Constructed and qualified with clinical and experimental data [2-16]
  - Mitochondrial biogenesis added as a potential adaptation pathway
- A solithromycin model was previously constructed within DILIsym [17]
  - Inhibits hepatic bile acid transporters and mitochondrial electron transport chain (ETC)
  - Simulations recapitulated clinically observed mild ALT elevations
- Metformin model was constructed within DILIsym using clinical PK and *in vitro* mechanistic toxicity data
- DILIsym simulations performed using SimPops (n=285) with protocols below in the absence and presence of mitochondrial biogenesis:
  - Metformin 1 g BID for 4 weeks
  - Solithromycin IV 400 mg on days 1-3, PO 800 mg on day 4, PO 400 mg on days 5-7 (IV-to-Oral protocol)
  - Metformin 1 g BID for 4 weeks + Solithromycin IV-to-Oral protocol during the 4<sup>th</sup> week

## DILIsym Mechanism-Based Model





## Mitochondrial Biogenesis Sub-model



# Results


- Therapeutic dose of metformin (1 g BID) alone induced mild ALT elevations in a subset of simulated individuals which resolved with biogenesis despite continuing treatment
  - Consistent with known liver safety of metformin
  - Metformin is an inhibitor of mitochondrial ETC
- Solithromycin IV-to-Oral protocol alone induced modest ALT elevations in a subset of simulated individuals which resolved with biogenesis despite continuing treatment
  - Consistent with clinically observed ALT dynamics (by design) [17,18]
- Metformin enhanced solithromycin-induced hepatotoxicity in a subset of simulated individuals
  - Simulated DILI DDI was mitigated by mitochondrial biogenesis
  - A subset of patients who developed ALT elevations in solithromycin trials had a history of metformin treatment, but detailed information is lacking
  - Observed ALT elevations were modest suggesting a potential role of biogenesis, but additional data are needed to better quantitate the impact of biogenesis

3X ULN (upper limit of normal) = 120 U/L



# Conclusion

- QST modeling can be employed to predict potential DILI DDIs due to interactions at toxicological mechanisms
- QST modeling can identify the potential mechanisms underlying DILI adaptation
  - More experimental data are needed to better quantitate the extent and inter-individual variability of biogenesis and to enhance the accuracy of prospective predictions of adaptation to DILI



# References

1. Cook, D. et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. *Nat Rev Drug Discov* 13, 419–431 (2014).
2. Howell, B. A. et al. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. *J Pharmacokinet Pharmacodyn* 39, 527–541 (2012).
3. Howell, B. A., Siler, S. Q. & Watkins, P. B. Use of a systems model of drug-induced liver injury (DILIsym®) to elucidate the mechanistic differences between acetaminophen and its less-toxic isomer, AMAP, in mice. *Toxicol. Lett.* 226, 163–172 (2014).
4. Woodhead, J. L. et al. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. *J. Pharmacol. Exp. Ther.* 342, 529–540 (2012).
5. Woodhead, J. L. et al. Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILI. *CPT Pharmacometrics Syst Pharmacol* 3, e123 (2014).
6. Yang, K., Woodhead, J. L., Watkins, P. B., Howell, B. A. & Brouwer, K. L. Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid-Mediated Troglitazone Hepatotoxicity. *Clin. Pharmacol. Ther.* 589–598 (2014) doi:10.1038/clpt.2014.158.
7. Woodhead, J. L. et al. Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury. *Front Pharmacol* 5, 240 (2014).
8. Longo, D. M., Yang, Y., Watkins, P. B., Howell, B. A. & Siler, S. Q. Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym®, a Mechanistic Model of Drug-Induced Liver Injury. *CPT Pharmacometrics Syst Pharmacol* 5, 31–39 (2016).
9. Woodhead, J. L. et al. Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors. *Toxicol. Sci.* 155, 61–74 (2017).
10. Watkins, P. B. The DILI-sim Initiative: Insights into Hepatotoxicity Mechanisms and Biomarker Interpretation. *Clin Transl Sci* 12, 122–129 (2019).
11. Battista, C. et al. Using Quantitative Systems Toxicology to Investigate Observed Species Differences in CKA-Mediated Hepatotoxicity. *Toxicol. Sci.* 166, 123–130 (2018).
12. Woodhead, J. L., Pellegrini, L., Shoda, L. K. M. & Howell, B. A. Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney Disease Using Quantitative Systems Toxicology Modeling. *Pharm. Res.* 37, 24 (2020).
13. Longo, D. M. et al. Quantitative Systems Toxicology Analysis of In Vitro Mechanistic Assays Reveals Importance of Bile Acid Accumulation and Mitochondrial Dysfunction in TAK-875-Induced Liver Injury. *Toxicol. Sci.* 167, 458–467 (2019).
14. Longo, D., Woodhead, J. L., Howell, B. A. & Shoda, L. K. M. Predicting the Hepatotoxic Potential of ESN-364 and ES259564 with the DILIsym® Software Platform. (2019).
15. Watkins, P. B. Quantitative Systems Toxicology Approaches to Understand and Predict Drug-Induced Liver Injury. *Clin Liver Dis* 24, 49–60 (2020).
16. Generaux, G. et al. Quantitative systems toxicology (QST) reproduces species differences in PF-04895162 liver safety due to combined mitochondrial and bile acid toxicity. *Pharmacology Research & Perspectives* 7, e00523 (2019).
17. Woodhead, J. L. et al. Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems Toxicology Modeling. *Pharm. Res.* 36, 48 (2019).
18. File, T. M. et al. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia. *Clin. Infect. Dis.* 63, 1007–1016 (2016).

# Acknowledgments

**Paul B. Watkins**  
DILI-sim Initiative Founder and  
Scientific Advisory Board Chair  
RTP, NC



**Scott Q Siler**  
Chief Scientific Officer  
Bay Area, CA



**Brett Howell**  
President  
RTP, NC



**Shawn O'Connor**  
CEO, Simulations Plus Inc.  
Lancaster, CA










**DILIsym Services**

**SP+** A SIMULATIONS PLUS COMPANY

**Jeff Woodhead**  
Senior Scientist  
RTP, NC



**Kyunghee Yang**  
Senior Scientist  
Lawrence, KS



**Lisl Shoda**  
Principal Scientist  
Director of Immunology  
Bay Area, CA



**Sergey Ermakov**  
Principal Scientist  
Bay Area, CA



**Christina Battista**  
Scientist II  
Buffalo, NY



**Zack Kenz**  
Scientist II  
Dubuque, Iowa



**Michael Liu**  
Senior Scientist  
RTP, NC



**Corey Berry**  
Senior Software  
Engineer  
RTP, NC



**Bud Nelson**  
Director of  
Operations  
RTP, NC



**Patti Steele**  
Executive Assistant  
RTP, NC



**Diane Longo**  
Senior Scientist  
Arlington, VA



**Yeshi Gebremichael**  
Scientist II  
RTP, NC



**Vinal Lakhani**  
Scientist I  
RTP, NC



**Nader Hamzavi**  
Postdoctoral Fellow  
RTP, NC



**Shailendra Tallapaka**  
Scientist I  
RTP, NC



**Pallavi Bhargava**  
Postdoctoral Fellow  
RTP, NC



**Lara Clemens**  
Postdoctoral Fellow  
RTP, NC



**James Beaudoin**  
Scientist I  
RTP, NC



# Questions

- Email: [kyang@DILIsym.com](mailto:kyang@DILIsym.com)
- Website: [www.DILIsym.com](http://www.DILIsym.com)

***DILIsym Services***

 A SIMULATIONS PLUS COMPANY